Dr. Olajide is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4420 Lake Boone Trl
Ste 200
Raleigh, NC 27607Phone+1 919-784-6818Fax+1 919-784-6826
Summary
- Dr. Oludamilola Olajide is an oncologist based in Raleigh, NC, specializing in hematology and medical oncology. She completed her medical education at the University of Ibadan, followed by a residency in internal medicine at the Medical College of Georgia and a fellowship at University of North Carolina Hospitals. She is currently employed as a Hematologist/Oncologist at UNC REX Health Care. Dr. Olajide has contributed to several publications, including studies on chemotherapy's cognitive effects and treatments for breast and Hodgkin lymphoma, with her work widely cited in various medical journals. Her main clinical and research focus is Breast cancer.
Education & Training
University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2003 - 2006
Medical College of GeorgiaResidency, Internal Medicine, 2000 - 2003
University of IbadanClass of 2000
Certifications & Licensure
NC State Medical License 2003 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Registry of Older Patients With Cancer Start of enrollment: 2009 Sep 01
- Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Start of enrollment: 2011 Feb 14
- Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma Start of enrollment: 2012 Apr 01
Publications & Presentations
PubMed
- 6 citationsA phase II single-arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, accep...Zev M Nakamura, Allison M Deal, Eliza M Park, Kate E Stanton, Yesy E Lopez
Cancer Medicine. 2023-04-01 - 11 citationsEvaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer.Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade
Journal for Immunotherapy of Cancer. 2022-02-01 - 21 citationsABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphomaSteven I. Park, Thomas C. Shea, Oludamilola Olajide, Nishitha Reddy, Lihua E. Budde
Blood Advances. 2020-06-09
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
